Prognostic and immunological significance of metastasis associated lung adenocarcinoma transcript 1 among different kinds of cancers

References

• Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8:1015.
   PubMed Web of Science ®Google Scholar
• Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2017;15:177–186.
   PubMed Web of Science ®Google Scholar
• Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19:143–157.
   PubMed Web of Science ®Google Scholar
• Sun Y, Ma L. New Insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers (Basel). 2019;11:216.
   PubMed Web of Science ®Google Scholar
• Gutschner T, Hämmerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180–1189.
   PubMed Web of Science ®Google Scholar
• Wu Y, Huang C, Meng X, et al. Long noncoding RNA MALAT1: insights into its biogenesis and implications in human disease. Curr Pharm Des. 2015;21:5017–5028.
   PubMed Web of Science ®Google Scholar
• Zhang X, Hamblin MH, Yin KJ. The long noncoding RNA Malat1: its physiological and pathophysiological functions. RNA Biol. 2017;14(12):1705–1714.
   PubMed Web of Science ®Google Scholar
• Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8031–8041.
   PubMed Web of Science ®Google Scholar
• Wu Q, Meng WY, Jie Y, et al. LncRNA MALAT1 induces colon cancer development by regulating miR-129-5p/HMGB1 axis. J Cell Physiol. 2018;233:6750–6757.
   PubMed Web of Science ®Google Scholar
• Feng C, Zhao Y, Li Y, et al. LncRNA MALAT1 promotes lung cancer proliferation and gefitinib resistance by acting as a miR-200a sponge. Arch Bronconeumol. 2019;55:627–633.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhu C, Jin Y. The oncogenic and tumor suppressive functions of the long noncoding RNA MALAT1: an emerging controversy. Front Genet. 2020;11:93.
   PubMed Web of Science ®Google Scholar
• Kwok ZH, Roche V, Chew XH, et al. A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers. Int J Cancer. 2018;143:668–678.
   PubMed Web of Science ®Google Scholar
• Zhang B, Arun G, Mao YS, et al. The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012;2:111–123.
   PubMed Web of Science ®Google Scholar
• Mun EJ, Babiker HM, Weinberg U, et al. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res. 2018;24:266–275.
   PubMed Web of Science ®Google Scholar
• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125:3335–3337.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17–35.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1–6.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e110.
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509–W514.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013 Dec 18;8(12):e82241.
   PubMed Web of Science ®Google Scholar
• Mizuno H, Kitada K, Nakai K, et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.
   PubMed Web of Science ®Google Scholar
• Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 2011;236:567–579.
   PubMed Web of Science ®Google Scholar
• Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206–221.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16:599–611.
   PubMed Web of Science ®Google Scholar
• Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26:94–109.
   PubMed Web of Science ®Google Scholar
• Pirie E, Ray S, Pan C, et al. Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1. PLoS Genet. 2018;14:e1007732.
   PubMed Web of Science ®Google Scholar
• Guo F, Li Y, Liu Y, et al. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin (Shanghai). 2010;42:224–229.
   PubMed Web of Science ®Google Scholar
• Jin D, Guo J, Wu Y, et al. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12:135.
   PubMed Web of Science ®Google Scholar
• Sun Z, Ou C, Liu J, et al. YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene. 2019;38:2627–2644.
   PubMed Web of Science ®Google Scholar
• Wu C, Zhu X, Tao K, et al. MALAT1 promotes the colorectal cancer malignancy by increasing DCP1A expression and miR203 downregulation. Mol Carcinog. 2018;57:1421–1431.
   PubMed Web of Science ®Google Scholar
• Jen J, Tang YA, Lu YH, et al. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer. 2017;16:104.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhao W, Chen S, et al. Expression and correlation of MALAT1 and SOX9 in non-small cell lung cancer. Clin Respir J. 2018;12:2284–2291.
   PubMed Web of Science ®Google Scholar
• Liu C, Li H, Jia J, et al. High metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) expression promotes proliferation, migration, and invasion of non-small cell lung cancer via ERK/mitogen-activated protein kinase (MAPK) signaling pathway. Med Sci Monit. 2019;25:5143–5149.
   PubMed Web of Science ®Google Scholar
• Tang Y, Xiao G, Chen Y, et al. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Anticancer Drugs. 2018;29:725–735.
   PubMed Web of Science ®Google Scholar
• Li S, Mei Z, Hu HB, et al. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol. 2018;233:6679–6688.
   PubMed Web of Science ®Google Scholar
• Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6:1984–1992.
   PubMed Web of Science ®Google Scholar
• Ou X, Gao G, Bazhabayi M, et al. MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer. J Cancer Res Ther. 2019;15:1597–1602.
   PubMed Web of Science ®Google Scholar
• Li X, Chen N, Zhou L, et al. Genome-wide target interactome profiling reveals a novel EEF1A1 epigenetic pathway for oncogenic lncRNA MALAT1 in breast cancer. Am J Cancer Res. 2019;9:714–729.
   PubMed Web of Science ®Google Scholar
• Arshi A, Sharifi FS, Khorramian Ghahfarokhi M, et al. Expression analysis of MALAT1, GAS5, SRA, and NEAT1 lncRNAs in breast cancer tissues from young women and women over 45 years of age. Mol Ther Nucleic Acids. 2018;12:751–757.
   PubMedGoogle Scholar
• Miao Y, Fan R, Chen L, et al. Clinical significance of long non-coding RNA MALAT1 expression in tissue and serum of breast cancer. Ann Clin Lab Sci. 2016;46:418–424.
   PubMed Web of Science ®Google Scholar
• Zidan HE, Karam RA, El-Seifi OS, et al. Circulating long non-coding RNA MALAT1 expression as molecular biomarker in Egyptian patients with breast cancer. Cancer Genet. 2018;220:32–37.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Li Y, Zhou Z, et al. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer. Biomed Pharmacother. 2017;95:922–928.
   PubMed Web of Science ®Google Scholar
• Wu Y, Sarkissyan M, Ogah O, et al. Expression of MALAT1 promotes trastuzumab resistance in HER2 overexpressing breast cancers. Cancers (Basel). 2020;12:1918.
   PubMed Web of Science ®Google Scholar
• Zeng L, Cen Y, Chen J. Long non-coding RNA MALAT-1 contributes to maintenance of stem cell-like phenotypes in breast cancer cells. Oncol Lett. 2018;15:2117–2122.
   PubMed Web of Science ®Google Scholar
• Kim J, Piao HL, Kim BJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50:1705–1715.
   PubMed Web of Science ®Google Scholar
• Eastlack SC, Dong S, Mo YY, et al. Expression of long noncoding RNA MALAT1 correlates with increased levels of Nischarin and inhibits oncogenic cell functions in breast cancer. PLoS One. 2018;13:e0198945.
   PubMed Web of Science ®Google Scholar
• Li XX, Wang LJ, Hou J, et al. Identification of long noncoding RNAs as predictors of survival in triple-negative breast cancer based on network analysis. Biomed Res Int. 2020;2020:8970340.
   PubMed Web of Science ®Google Scholar
• Ma R, Zhang BW, Zhang ZB, et al. LncRNA MALAT1 knockdown inhibits cell migration and invasion by suppressing autophagy through miR-384/GOLM1 axis in glioma. Eur Rev Med Pharmacol Sci. 2020;24:2601–2615.
   PubMed Web of Science ®Google Scholar
• Fu Z, Luo W, Wang J, et al. Malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma. Biochem Biophys Res Commun. 2017;492:480–486.
   PubMed Web of Science ®Google Scholar
• Li Z, Xu C, Ding B, et al. Long non-coding RNA MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101. J Neurooncol. 2017;134:19–28.
   PubMed Web of Science ®Google Scholar
• Cao S, Wang Y, Li J, et al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. Am J Cancer Res. 2016;6:2561–2574.
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhao H, Xiao X, et al. Long non-coding RNA MALAT1 upregulates ZEB2 expression to promote malignant progression of glioma by attenuating miR-124. Mol Neurobiol  2021;58:1006–16.
   Google Scholar
• Xiang J, Guo S, Jiang S, et al. Silencing of long non-coding RNA MALAT1 promotes apoptosis of glioma cells. J Korean Med Sci. 2016;31:688–694.
   PubMed Web of Science ®Google Scholar
• Han Y, Wu Z, Wu T, et al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. 2016;7:e2123.
   PubMed Web of Science ®Google Scholar
• Zhu K, Ren Q, Zhao Y. lncRNA MALAT1 overexpression promotes proliferation, migration and invasion of gastric cancer by activating the PI3K/AKT pathway. Oncol Lett. 2019;17:5335–5342.
   PubMed Web of Science ®Google Scholar
• Chen D, Liu L, Wang K, et al. The role of MALAT-1 in the invasion and metastasis of gastric cancer. Scand J Gastroenterol. 2017;52:790–796.
   PubMed Web of Science ®Google Scholar
• Deng QJ, Xie LQ, Li H. Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression. Life Sci. 2016;157:38–44.
   PubMed Web of Science ®Google Scholar
• Li X, Zhao J, Zhang H, et al. Silencing of LncRNA metastasis-associated lung adenocarcinoma transcript 1 inhibits the proliferation and promotes the apoptosis of gastric cancer cells through regulating microRNA-22-3p-mediated ErbB3. Onco Targets Ther. 2020;13:559–571.
   PubMed Web of Science ®Google Scholar
• Wu S, Sun H, Wang Y, et al. MALAT1 rs664589 polymorphism inhibits binding to miR-194-5p, contributing to colorectal cancer risk, growth, and metastasis. Cancer Res. 2019;79:5432–5441.
   PubMed Web of Science ®Google Scholar
• Li C, Cui Y, Liu LF, et al. High expression of long noncoding RNA MALAT1 indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer. Clin Genitourin Cancer. 2017;15:570–576.
   PubMed Web of Science ®Google Scholar
• Huang C, Yu Z, Yang H, et al. Increased MALAT1 expression predicts poor prognosis in esophageal cancer patients. Biomed Pharmacother. 2016;83:8–13.
   PubMed Web of Science ®Google Scholar
• Wang WW, Zhou XL, Song YJ, et al. Combination of long noncoding RNA MALAT1 and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer. Onco Targets Ther. 2018;11:2333–2344.
   PubMed Web of Science ®Google Scholar
• Dai SP, Jin J, Li WM. Diagnostic efficacy of long non-coding RNA in lung cancer: a systematic review and meta-analysis. Postgrad Med J. 2018;94:578–587.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Chen Y, et al. LncRNA MALAT1 exerts oncogenic functions in lung adenocarcinoma by targeting miR-204. Am J Cancer Res. 2016;6:1099–1107.
   PubMed Web of Science ®Google Scholar
• Jadaliha M, Zong X, Malakar P, et al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget. 2016;7:40418–40436.
   PubMed Web of Science ®Google Scholar
• Wang Z, Katsaros D, Biglia N, et al. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival. Breast Cancer Res Treat. 2018;171:261–271.
   PubMed Web of Science ®Google Scholar
• Toraih EA, El-Wazir A, Ageeli EA, et al. Unleash multifunctional role of long noncoding RNAs biomarker panel in breast cancer: a predictor classification model. Epigenomics. 2020;12:1215–1237.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79:4557–4566.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ. Tumor microenvironment, metabolism, and immunotherapy. N Engl J Med. 2020;382:869–871.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun D, Zhu Q, et al. The screening of immune-related biomarkers for prognosis of lung adenocarcinoma. Bioengineered. 2021;12:1273–1285.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–1022.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Dai Z, Locasale JW. Metabolic landscape of the tumor microenvironment at single cell resolution. Nat Commun. 2019;10:3763.
   PubMed Web of Science ®Google Scholar
• Marelli G, Howells A, Lemoine NR, et al. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front Immunol. 2018;9:866.
   PubMed Web of Science ®Google Scholar
• Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–68.
   PubMed Web of Science ®Google Scholar
• Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368:7–13.
   PubMed Web of Science ®Google Scholar
• Locy H, de Mey S, de Mey W, et al. Immunomodulation of the tumor microenvironment: turn foe into friend. Front Immunol. 2018;9:2909.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Iyoda T, Okada M, et al. Immune suppression and reversal of the suppressive tumor microenvironment. Int Immunol. 2018;30:445–454.
   PubMed Web of Science ®Google Scholar
• Bernardini G, Zabel BA. Editorial: the role of chemoattractants in the tumor microenvironment. Front Immunol. 2019;10:2671.
   PubMed Web of Science ®Google Scholar
• Zhang C, Ren X, Zhang W, et al. Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers. Bioengineered. 2020;11:1112–1123.
   PubMed Web of Science ®Google Scholar
• Xie ZC, Dang YW, Wei DM, et al. Clinical significance and prospective molecular mechanism of MALAT1 in pancreatic cancer exploration: a comprehensive study based on the GeneChip, GEO, oncomine, and TCGA databases. Onco Targets Ther. 2017;10:3991–4005.
   PubMed Web of Science ®Google Scholar